Table S1. Primer sequences

Similar documents
Fig. S1. eif6 expression in HEK293 transfected with shrna against eif6 or pcmv-eif6 vector.

Fig. S1. Effect of p120-catenin overexpression on the interaction of SCUBE2 with E-cadherin. The expression plasmid encoding FLAG.

SUPPLEMENTARY INFORMATION

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1.

Site-Directed Mutagenesis. Mutations in four Smad4 sites of mouse Gat1 promoter

ChampionChIP Quick, High Throughput Chromatin Immunoprecipitation Assay System

Nature Biotechnology: doi: /nbt Supplementary Figure 1

Regulation of transcription by the MLL2 complex and MLL complex-associated AKAP95

Cell proliferation was measured with Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan).

Supplementary Materials for

Supplementary Table S1

a. Increased active HPSE (50 kda) protein expression upon infection with multiple herpes viruses: bovine

- 1 - Supplemental Data

Control + SDS + 2BME. Control + SDS. Control

Contents... vii. List of Figures... xii. List of Tables... xiv. Abbreviatons... xv. Summary... xvii. 1. Introduction In vitro evolution...

WT Day 90 after injections

Li et al., Supplemental Figures

Supplementary Figure 1. ips_3y+mir-302b. ips_3y+mir-372. ips_3y+mir-302b + mir-372. ips_4y. ips_4y+mir-302b. ips_4y + mir-372

Supplementary Information

Supplementary Methods

Supplementary Figure 1 Validate the expression of mir-302b after bacterial infection by northern

The RRPA knock-in allele was generated by homologous recombination in TC1 ES cells.

Supplemental Information. The TRAIL-Induced Cancer Secretome. Promotes a Tumor-Supportive Immune. Microenvironment via CCR2

(a) Immunoblotting to show the migration position of Flag-tagged MAVS

RNA was isolated using NucleoSpin RNA II (Macherey-Nagel, Bethlehem, PA) according to the

Supplementary data. sienigma. F-Enigma F-EnigmaSM. a-p53

Supplementary Fig. 1 related to Fig. 1 Clinical relevance of lncrna candidate

b alternative classical none

Regulation of hepcidin expression by inflammation-induced activin B

Supplementary Data Supplementary Figure 1. Knockdown of VentX with a different sirna sequence reduces terminal monocyte to macrophage

A Repressor Complex Governs the Integration of

Flowcytometry-based purity analysis of peritoneal macrophage culture.

Supplemental data. Zhao et al. (2009). The Wuschel-related homeobox gene WOX11 is required to activate shoot-borne crown root development in rice.

Mammosphere formation assay. Mammosphere culture was performed as previously described (13,

Figure S1. nuclear extracts. HeLa cell nuclear extract. Input IgG IP:ORC2 ORC2 ORC2. MCM4 origin. ORC2 occupancy

Nature Genetics: doi: /ng Supplementary Figure 1. ChIP-seq genome browser views of BRM occupancy at previously identified BRM targets.

IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity

Selected Techniques Part I

Supplementary Figure 1 Phosphorylated tau accumulates in Nrf2 (-/-) mice. Hippocampal tissues obtained from Nrf2 (-/-) (10 months old, 4 male; 2

SUPPLEMENTARY INFORMATION

Transcriptional regulation of BRCA1 expression by a metabolic switch: Di, Fernandez, De Siervi, Longo, and Gardner. H3K4Me3

Table 1. Primers, annealing temperatures, and product sizes for PCR amplification.

cells (MLEC) that produce luciferase under the control of the PAI-1 promoter in response to

supplementary information

TRIM31 is recruited to mitochondria after infection with SeV.

Table S1. Primers used in RT-PCR studies (all in 5 to 3 direction)

Molecular Cell Biology - Problem Drill 11: Recombinant DNA

At E17.5, the embryos were rinsed in phosphate-buffered saline (PBS) and immersed in

Personal Exam Code: 1. 16p

Fig. S1 TGF RI inhibitor SB effectively blocks phosphorylation of Smad2 induced by TGF. FET cells were treated with TGF in the presence of

Supplemental Figure legends Figure S1. (A) (B) (C) (D) Figure S2. Figure S3. (A-E) Figure S4. Figure S5. (A, C, E, G, I) (B, D, F, H, Figure S6.

Transcriptional Regulation of Pro-apoptotic Protein Kinase C-delta: Implications for Oxidative Stress-induced Neuronal Cell Death

Supplementary Data. Flvcr1a TCTAAGGCCCAGTAGGACCC GGCCTCAACTGCCTGGGAGC AGAGGGCAACCTCGGTGTCC

HPV E6 oncoprotein targets histone methyltransferases for modulating specific. Chih-Hung Hsu, Kai-Lin Peng, Hua-Ci Jhang, Chia-Hui Lin, Shwu-Yuan Wu,

supplementary information

SUPPLEMENTAL FIGURES AND TABLES

administration of tamoxifen. Bars show mean ± s.e.m (n=10-11). P-value was determined by

Nature Immunology: doi: /ni Supplementary Figure 1. Zranb1 gene targeting.

Electromagnetic Fields Mediate Efficient Cell Reprogramming Into a Pluripotent State

File name: Supplementary Information Description: Supplementary figures and supplementary tables. File name: Peer review file Description:

ASPP1 Fw GGTTGGGAATCCACGTGTTG ASPP1 Rv GCCATATCTTGGAGCTCTGAGAG

CFTR-null wt CFTR-null 1.0. Probe: Neo R. Figure S1

RNA oligonucleotides and 2 -O-methylated oligonucleotides were synthesized by. 5 AGACACAAACACCAUUGUCACACUCCACAGC; Rand-2 OMe,

Supplemental Table/Figure Legends

Chemically defined conditions for human ipsc derivation and culture

Figure S1. Figure S2. Figure S3 HB Anti-FSP27 (COOH-terminal peptide) Ab. Anti-GST-FSP27(45-127) Ab.

Supplementary Figure 1, related to Figure 1. GAS5 is highly expressed in the cytoplasm of hescs, and positively correlates with pluripotency.

8Br-cAMP was purchased from Sigma (St. Louis, MO). Silencer Negative Control sirna #1 and

Supplemental Figure 1 HDA18 has an HDAC domain and therefore has concentration dependent and TSA inhibited histone deacetylase activity.

Jung-Nam Cho, Jee-Youn Ryu, Young-Min Jeong, Jihye Park, Ji-Joon Song, Richard M. Amasino, Bosl Noh, and Yoo-Sun Noh

HCT116 SW48 Nutlin: p53

Supplementary Figure 1

Confocal immunofluorescence microscopy

Supplementary Figure 1 PARP1 is involved in regulating the stability of mrnas from pro-inflammatory cytokine/chemokine mediators.

Methods for Working with DNA and RNA

Khaled_Fig. S MITF TYROSINASE R²= MITF PDE4D R²= Variance from mean mrna expression

SUPPLEMENTARY INFORMATION

Supplementary Figure Legends. Figure-S1 Molecular basis of ASS1 deficiency in myxofibrosarcoma: (A)

Supplementary Figure 1

Accelerating skin wound healing by M-CSF through generating SSEA-1 and -3 stem cells. in the injured sites

Supplementary Figure 1. jmj30-2 and jmj32-1 produce null mutants. (a) Schematic drawing of JMJ30 and JMJ32 genome structure showing regions amplified

hours after food deprivation hours after food deprivation

The Biotechnology Toolbox

transcription and the promoter occupancy of Smad proteins. (A) HepG2 cells were co-transfected with the wwp-luc reporter, and FLAG-tagged FHL1,

Supplementary Figure 1 a. d 0.8 CON LPS PAN. 2nd ab nephrin podocin CON LPS PAN. upar. -tubulin. upar. upar / -tubulin CON LPS PAN

SUPPLEMENTARY INFORMATION

Wnt16 smact merge VK/AB

used at a final concentration of 5 ng/ml. Rabbit anti-bim and mouse anti-mkp2 antibodies were

Supplementary information Activation of AMP-activated protein kinase

Bootcamp: Molecular Biology Techniques and Interpretation

Table S1. Primers used in the study

Supplementary Information. A novel human endogenous retroviral protein inhibits cell-cell fusion. Supplementary Figures:

Supplementary Figure 1. TRIM9 does not affect AP-1, NF-AT or ISRE activity. (a,b) At 24h post-transfection with TRIM9 or vector and indicated

Post-translational modification

Genomic DNA fragments identified by ChIP-chip assay for MR [28] corresponding to two

Supplemental Table S1. RT-PCR primers used in this study

Supplementary Fig.1. Over-expression of RNase L in stable polyclonal cell line

Supplementary Table 1. PCR amplification conditions for each primer pair. Primer sequence

SUPPLEMENTARY INFORMATION

Transcription:

Table S1. Primer sequences Primers for quantitative PCR Tgf 1 Forward Tgf 1 Reverse Tgf 2Forward Tgf 2Reverse Tgf 3 Forward Tgf 3 Reverse Tgf r1 Forward Tgf r1 Reverse Tgf r2 Forward Tgf r2 Reverse Thbs1 Forward Thbs1 Reverse Acta2 Forward Acta2 Reverse Cnn1 Forward Cnn1 Reverse DH4S114 Forward DH4S114 Reverse Smad6 Forward Smad6 Reverse Ctgf Forward Ctgf Reverse Hmox1 Forward Hmox1 Reverse p21 Forward p21 Reverse Fn1 Forward Fn1 Reverse Ccl2 Forward Ccl2 Reverse Ccl7 Forward Ccl7 Reverse Il6 Forward Il6 Reverse I B Forward I B Reverse RelB Forward RelB Reverse Mt1 Forward Mt1 Reverse Mt2 Forward Mt2 Reverse Sod1 Forward 5'AACCGCACTGTCATTCACC 3' 5'CGCCAA ACTTCTCCA AACC 3' 5'CTCAACACACCAAAGTCCTC 3' 5'ATCAAAACTCCCTCCCTCC 3' 5'ACCAAAGCGACAGACCTCAC 3' 5'TTCCCCTAACCAACCCACAC 3' 5'AACCGCACTGTCATTCACC 3' 5'CGCCAA ACTTCTCCA AACC 3' 5'AAGGAA AAGAAAAGGGCGG 3' 5'GCACACGGTAGCAGTAGA AG 3' 5'TGCCCAAAGGGAGAAAGTCCAGAA 3' 5'CTGAGCAGCACACACAGAAGCATT 3' 5'TTGCTGACAGGATGCAGAAGGAGA 3' 5'TCACAGTTGTGTGCTAGAGGCAGA 3' 5'TTGTGGATGTGACAGCAGCGTTTG 3' 5'TGTATCACATGGCCTGTGTGTGGA 3' 5'AGGCCTTGTTCTGAACTGTTTGCG 3' 5'GCAGCGCACACTGCAATTCTACAT 3' 5'ACCGGGTTACTCCATCAAGGTGTT 3' 5'GCCGCATTGCTATCTGTGGTTGTT 3' 5'GACAGCTTGTGGCAAGTGAA 3' 5'TTCCTCGTGGAAATCTGACC 3' 5'AGGTGATGCTGACAGAGGAACACA 3' 5'ACAGAGAGAAGGCCACATTGGACA 3' 5'TTGTCGCTGTCTTGCACTC3' 5'AGGTTTGGAGACTGGGAGAG3' 5'TTTTGACAACGGGAAGCATTATCAGATAA 3' 5'TGATCAAAACATTTCTCAGCTATTGG 3' 5'TCACCTGCTGCTACTCATTCACCA 3' 5'AAAGGTGCTGAAGACCTTAGGGCA 3' 5'CCCAATGCATCCACATGCTGCTAT 3' 5'TGCTTCTTGGCTCCTAGGTTGGTT 3' 5'ACCACTTCACAAGTCGGAGGCTTA 3' 5'TGGTACTCCAGAAGACCAGAGGAA 3' 5'ATCCTGACCTGGTTTCGCTCTTGT 3' 5'ACACAGTCATCATAGGGCAGCTCA 3' 5'GCGGATTTGCCGAATCAACAAGGA 3' 5'AACACATTGACAGTCACGGGCTCT 3' 5'AGCTTCACCAGATCTCGGAATGGA 3' 5'ACGCTGGGTTGGTCCGATACTATT 3' 5'TGGCCATATCCCTTGAGCCAGAAA 3' 5'TTGTCGGAAGCCTCTTTGCAGATG 3' 5'TGGCGATGAAAGCGGTGTGC 3'

Sod1 Reverse Sod2 Forward Sod2 Reverse Gapdh Forward Gapdh Reverse Nox1 Forward Nox1 Reverse Nox2 Forward Nox2 Reverse Nox4 Forward Nox4 Reverse Rac1 Forward Rac1 Reverse Rac2 Forward Rac2 Reverse 5'GCGGCTCCCAGCATTTCCAG 3' 5'GCACATTAACGCGCAGATCA 3' 5'AGCCTCCAGCAACTCTCCTT 3' 5'AACGACCCCTTCATTGACC 3' 5'TGAAGACACCAGTAGACTCC 3' 5'TGGATGGATCTCTCGCTTCT3' 5'TCACCCAAGCTCTCCTCTGT3' 5'CTTTCTCAGGGGTTCCAGTG3' 5'TGCAGTCTATCATCCAAGC3' 5'CCAGAATGAGGATCCCAGAA3' 5'CAGCAGCAGCATGTAGAAGAC3' 5'TATGGGACACAGCTGGACAA3' 5'TTGAGTCCTCGCTGTGTGAC3' 5'CATCAGCTACACCACCAACG3' 5'TCTCGATGGTGTCCTTGTCA3' Primers used in CHIP Tgf 2 promoter 1143 813 Forward Tgf 2 promoter 1143 813 Reverse Tgf 2 promoter 87 37 Forward Tgf 2 promoter 87 37 Reverse Tgf 2 promoter 189 94 Forward Tgf 2 promoter 189 94 Reverse Mt1 promoter 183 168 Forward Mt1 promoter 183 168 Reverse Sod2 promoter 236 1 Forward Sod2 promoter 236 1 Reverse Sod2 intron 2161 2498 Forward Sod2 intron 2161 2498 Reverse 5' CTGCAACAACAGACCTCACTTCCT 3' 5' TCTTTCTTCCCACTGGTCTTTCCC 3' 5' TCGTGGCCACAGAGTCATCACTAA 3' 5' ACACACACACACACACACACACAC 3' 5' ACTGCAAATTCCTCATGCCAGTCG 3' 5' TCTCAGCGCCTTCTCTCTTTCTCT 3' 5' TGGGTTTACGGAGATAGCTGGCTT 3' 5' ACGTTGAAGTCGTGGTGACGCTTA 3' 5' AATTCTGACCAGCAGCAGAGCCTT 3' 5' TGTGCCAAATTGGTAGAGGCCG 3' 5' TGTGGTTGCTGGACCTTTGGAAGA 3' 5' AGGAAATGCTTTCCCAACTGGGCT 3' Primers used for bisulfite sequencing Tgfβ2 BS Forward Tgfβ2 BS Forward 5' AAGAGTTATTTTGGAGTAATTTATTTG 3' 5' ACTACCTACAAAAAAAACCAACCTC 3' Primers used for measurements of mouse telomere Mouse telomere F Mouse telomere R Mouse 36B4 F Mouse 36B4 R 5'CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT3' 5'GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT3' 5'ACTGGTCTAGGACCCGAGAAG3' 5'TCAATGGTGCCTCTGGAGATT3'

Figure S1. Upregulation of TGFβtarget genes in the IKKβnull cells. RNA isolated from wild type and Ikkβ / cells were examined by realtime qrtpcr for expression of genes of the TGFβ pathway. Fold change over uninfected cells was calculated based on data from biological triplicates. Results represent the mean values ± SD from at least two independent experiments. **p<.1 and p<.1 was considered significant. Figure S2. Induction of IKKβ loss in vitro. The Ikkβ F/F fibroblasts were infected with AdGFP and AdCre with or without coinfection with AdIKKβ for 48 h. (A) The infected cells were photographed under light and fluorescence microscopy. More than 9% Ikkβ F/F /AdGFP cells were shown to be GFP positive. (B) The Ikkβ F/F, Ikkβ F/F /AdCre (infected for 48 h) and Ikkβ / cells were treated with TNFα for various times; cell lysates were analyzed by Western blotting for IKKβ, IκBα and βactin. The uninfected or infected Ikkβ F/F cells were used for (C) RNA isolation and analyzed by realtime RTPCR for Ikkβ expression, and (D) transfection with κb Luc reporter and βgal expression plasmid. The Luc and βgal activities were examined 24 h after transfection, and the relative Luc activity (versus βgal activity) was calculated. Fold change over uninfected cells was calculated based on data from biological triplicates. (E) After AdCre infection, the Ikkβ F/F /AdCre cells were passage in vitro for various lengths of time and without or with IKKβ reexpression (AdIKKβ infection). RNA was isolated and analyzed by realtime RTPCR for the expression of NFκBtarget genes. Results represent the mean values ± SD from at least two independent experiments. p<.1 was considered significant. Figure S3. Genotyping of Ikkβ F/F /Tgfβr2 F/F /AdGFP and Ikkβ F/F /Tgfβr2 F/F /AdCre fibroblasts. Genomic DNAs were used for PCR genotyping, using primers recognizing the Ikkβ F, Ikkβ Δ, Tgfβr2 F and Tgfβr2 Δ alleles, and primers for Gapdh. The PCR products were examined on agarose gel after electrophoresis.

Figure S4. Induction of IKKβ loss leads to progressive ROS elevation. (A) The wild type cells with and without H 2 O 2 (1 um) treatment for 6 h and the Ikkβ(/) cells with or without AdIKKβ infection for 24 h, and (B) the Ikkβ F/F cells with or without AdCre infection, were labeled with CMH 2 DCFDA and analyzed by flow cytometry at 485/53 nm. y axis, cell numbers, x axis, fluorescence intensity. (C) The cells were divided to two groups based on the level of DCF intensity: the DCFhigh (M2) and DCFlow (M1). The percentage of cells in each group was calculated. Results represent the mean values ± SD from at least two independent experiments. *: p<.5 was considered significant. Figure S5. Increased TGFβ target gene expression and migration of the p65null cells. (A) RNA isolated from wild type and p65 / fibroblasts were analyzed by RTPCR for selected genes of the TGFβ pathways. (B) The cells were subjected to in vitro wound healing assays, and healing rate was calculated by comparison of the wound sizes at and 12 h of wounding. Results represent the mean values ± SD from at least two independent experiments. : p <.1 were considered significant. Figure S6. IKKβ loss induces cjun binding and H3K4Me3 modification of the Tgfβ2 promoter (A) Illustration of approximate locations of potential AP1 binding sites in the Tgfβ2 promoter. The Ikkβ F/F and Ikkβ F/F /AdCre cells were subjected to Chromatinimmunoprecipitation (ChIP) assay using antibodies for (B) transcription factors, p65, p5, Nrf2 and cjun, and (C) histone markers, H3K27Me3, H3K9Me2 and H3K4Me3. The precipitates were examined by PCR using primers for various regions of the Tgfβ2 promoter. The data were calculated as percentage of input and represented the mean values ± SD from at least two independent experiments. p <.1 were considered significant.

Relative mrna level 14 12 1 WT Ikk / 8 6 4 2 ** Chen, et. al. Supplemental Figure 1

Relative luc activity Relative mrna Relative Ikk mrna A C D 2 μm 2. 1.5 1..5 AdGFP AdCre 2.5 2. 1.5 1..5 AdGFP AdCre AdIKK AdGFP B Ikk F/F B binding siteluc E TNF (h) IKK 5. 4.5 4. 3.5 3. 2.5 2. 1.5 1..5 I B actin.3 2.3 2.3 2 control AdCre_3 days AdCre_9 days AdCre_9 days_adikk Ikk F/F /AdCre Ikk / Ikk F/F Ccl2 Ccl7 Il6 I B RelB Chen, et. al. Supplemental Figure 2

Ikk F AdGFP Ikk F/F /Tgf r2 F/F AdCre Ikk Tgf r2 F Tgf r2 Gapdh Chen, et. al. Supplemental Figure 3

A B Ikk F/F WT WT_H 2 O 2 Ikk (/) Ikk (/)_AdIKK Control AdCre(3 days) AdCre(9 days) C M1 (Low DCFDA) M2 (High DCFDA) WT 73.35% 24.12% WT_H 2 O 2 44.6% 53.32% Ikk (/) 47.5% 5.54% Ikk (/)_AdIKK 87.9% 11.33% Ikk F/F 73.41% 24.2% Ikk F/F _AdCre_3 days 61.14% 36.7% Ikk F/F _AdCre_9 days 47.7% 49.57% Chen, et. al., Supplemental Figure 4

Relative mrna Wound closure % A 12 1 WT p65 / B 1 8 8 6 6 4 2 * 4 2 WT p65(/) Chen, et. al., Supplemental Figure 5

% of input % of input A B 1 Control AdCre (18 days) Tgf 2 promoter AP1 Tgf 2 promoter AP1.1 2 1 1.1.1 p65 p5 Nrf2 cjun IgG p65 p5 Nrf2 cjun IgG p65 p5 Nrf2 cjun IgG C 1 control AdCre (18 days) 1145 799 87 372 189 94 Tgf 2 promoter 1 1.1 **.1.1 1145 799 87 372 189 94 Chen, et. al. Supplemental Figure 6

2024 © businessdocbox.com Privacy Policy | Terms of Service | Feedback